Study | Therapy in experimental group | Therapy in control group | Country | Sample size | Administration method | Duration of treatment | Dosage | Stone location and size range | |
---|---|---|---|---|---|---|---|---|---|
experimental | Control | ||||||||
Itoh Y 2011 | silodosin | blank control | Japan | 95 | 92 | Oral | 8 wk | 8mg/d | symptomatic unilateral ureteral calculi of less than 10 mm |
Tsuzaka Y 2011 | silodosin | naftopidil | Japan | 35 | 39 | Oral | 6 wk | 8mg/d | symptomatic≤10 mm ureteral stones |
Guptas S 2013 | silodosin | tamsulosin | India | 50 | 50 | Oral | 4 wk | 8mg/d | unilateral, uncomplicated middle or lower ureteral stones ≤10 mm |
Dell'Atti L 2014 | silodosin | tamsulosin | Italy | 68 | 68 | Oral | 3 wk | 8mg/d | single, unilateral, radiopaque, proximal ureteral stone (range 4–10 mm in size) |
Sur RL 2014 | silodosin | placebo | USA | 119 | 120 | Oral | 4 wk | 8mg/d | unilateral ureteral calculus of 4–10 mm |
Kumar S 2015 | silodosin | tamsulosin | India | 90 | 90 | Oral | 4 wk | 8mg/d | distal ureteric stones of size 5–10 mm |